Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia

被引:2389
作者
Cheson, BD [1 ]
Bennett, JM
Kopecky, KJ
Büchner, T
Willman, CL
Estey, EH
Schiffer, CA
Döhner, H
Tallman, MS
Lister, TA
LoCocco, F
Willemze, R
Biondi, A
Hiddemann, W
Larson, RA
Löwenberg, B
Sanz, MA
Head, DR
Ohno, R
Bloomfield, CD
机构
[1] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Hematol Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[4] St Bartholomews Hosp, London, England
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[6] Univ New Mexico, Canc Treatment & Res Ctr, Albuquerque, NM 87131 USA
[7] Univ Valencia, Hosp Univ La Fe, Valencia, Spain
[8] Northwestern Univ, Chicago, IL 60611 USA
[9] Univ Chicago, Chicago, IL 60637 USA
[10] Inst Hematol, Rotterdam, Netherlands
[11] Erasmus MC, Rotterdam, Netherlands
[12] Leiden Univ, Leiden, Netherlands
[13] Univ Monza, Bicocca, Osped S Gerardo, Clin Pediat, Monza, Italy
[14] Univ Roma Tor Vergata, Rome, Italy
[15] Univ Ulm, Ulm, Germany
[16] Univ Grosshadern, Munich, Germany
[17] Univ Munster, D-4400 Munster, Germany
[18] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA
[19] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[20] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[21] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
关键词
D O I
10.1200/JCO.2003.04.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:4642 / 4649
页数:8
相关论文
共 44 条
[41]   All-trans retinoic acid in acute promyelocytic leukemia:: long-term outcome and prognostic factor analysis from the North American Intergroup protocol [J].
Tallman, MS ;
Andersen, JW ;
Schiffer, CA ;
Appelbaum, FR ;
Feusner, JH ;
Woods, WG ;
Ogden, A ;
Weinstein, H ;
Shepherd, L ;
Willman, C ;
Bloomfield, CD ;
Rowe, JM ;
Wiernik, PH .
BLOOD, 2002, 100 (13) :4298-4302
[42]   Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].
Thiede, C ;
Steudel, C ;
Mohr, B ;
Schaich, M ;
Schäkel, U ;
Platzbecker, U ;
Wermke, M ;
Bornhäuser, M ;
Ritter, M ;
Neubauer, A ;
Ehninger, G ;
Illmer, T .
BLOOD, 2002, 99 (12) :4326-4335
[43]   The World Health Organization (WHO) classification of the myeloid neoplasms [J].
Vardiman, JW ;
Harris, NL ;
Brunning, RD .
BLOOD, 2002, 100 (07) :2292-2302
[44]  
Whitman SP, 2001, CANCER RES, V61, P7233